Overview
Recordati Industria Chimica e Farmaceutica S.p.A., based in Italy, operates as a prominent pharmaceutical company with a specialized focus on the development, manufacturing, and marketing of pharmaceuticals within various therapeutic areas such as cardiovascular, urology, and dermatology. With a robust international presence, the company’s activities encompass both proprietary medicines and generic pharmaceuticals. Recordati consistently engages in strategic projects aimed at expanding its product portfolio through research and development initiatives, as well as licensing agreements. A notable aspect of its growth strategy includes acquiring assets and stakes in companies to solidify its market position across Europe and extend its footprint globally, furthering its reach in the pharmaceutical industry.
AI+ Ask Fintel’s AI assistant about Recordati Industria Chimica e Farmaceutica S.p.A..
Thinking about good questions…
Basic Stats
The share price of Recordati Industria Chimica e Farmaceutica S.p.A. as of 10 July 2025 is € 54,30 / share. The market cap (or net worth) of Recordati Industria Chimica e Farmaceutica S.p.A. as of 10 July 2025 is € 11.181,08 MM.
The Factor Analysis chart (below right) shows a view of Recordati Industria Chimica e Farmaceutica S.p.A. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 11,181.08 MM |
| EV | 13,236.50 MM |
| Shares Out. | 205.91 MM |
| Earnings Date | |
| EPS (TTM) | 2.03 |
| Dividend Yield | 4.66 % |
| Ex-Dividend Date | 2025-05-19 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.08 |
| Beta | -0.30 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | 26.81 |
| Price/Book | 5.67 |
| Price/TBV | -8.70 |
| Book/Market | 0.18 |
| EBIT/EV | 0.04 |
| EBIT(3yr avg)/EV | 0.04 |
| ROA | 0.10 |
| ROE | 0.23 |
| ROIC | 0.10 |
| CROIC | 0.01 |
| OCROIC | 0.13 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | 96.88 /100 |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 6.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Recordati Industria Chimica e Farmaceutica S.p.A.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-11-27 | EQUITA SIM | Buy | Buy | Maintains |
| 2023-11-08 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2023-08-04 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2023-08-03 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2023-08-02 | EQUITA SIM | Buy | Buy | Maintains |
| 2023-08-02 | CREDIT SUISSE - EUROPE | Underperform | Underperform | Maintains |
| 2023-08-01 | EQUITA SIM | Buy | Buy | Maintains |
| 2023-08-01 | CREDIT SUISSE - EUROPE | Underperform | Underperform | Maintains |
| 2023-06-01 | EQUITA SIM | Buy | Buy | Maintains |
| 2023-05-31 | EQUITA SIM | Buy | Buy | Maintains |
| 2023-05-12 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2023-05-12 | CREDIT SUISSE - EUROPE | Underperform | Underperform | Maintains |
| 2023-05-11 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2023-05-11 | CREDIT SUISSE - EUROPE | Underperform | Underperform | Maintains |
| 2024-08-04 | EQUITA SIM | Buy | Buy | Maintains |
| 2024-07-30 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2023-11-26 | EQUITA SIM | Buy | Buy | Maintains |
| 2023-11-07 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2024-11-27 | EQUITA SIM | Buy | Buy | Maintains |
| 2024-10-31 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2025-03-09 | JEFFERIES | Hold | Hold | Maintains |
| 2025-02-18 | EQUITA SIM | Buy | Buy | Maintains |
| 2025-02-06 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Hold | Maintains |
| 2025-06-26 | EQUITA SIM | Buy | Buy | Maintains |
| 2025-05-27 | JEFFERIES | Hold | Hold | Maintains |
| 2025-05-21 | INTESA SANPAOLO EQUITY RESEARCH | Hold | Neutral | Maintains |
